Should You Buy CorMedix Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, CorMedix Inc. (CRMD) scores a robust 9.0/10 on our 32-signal Quality of Company framework. At the current market price of $7.76 and a $605M market cap, our analysis maps this fundamental strength against 13 institutional-grade models to determine if a sufficient margin of safety exists.
The short answer: 8 of 10 CirclFi valuation models project upside for CorMedix Inc. (CRMD) at $7.76 — the model consensus leans bullish, with a Quality Score of 9.0/10 and Value-Trap risk of 18/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for CorMedix Inc. (CRMD) in 2026?
What Is the Bull Case vs the Bear Case for CorMedix Inc. (CRMD)?
| Bull case — $20.08 target (+158.8%) | Bear case — $0.26 target (-96.6%) |
|---|---|
| According to the CirclFi Quality of Company (QOC) framework, CorMedix Inc.'s rating of 9.0/10 signals strong fundamentals — high-quality businesses tend to compound value more reliably. | According to the CirclFi Deep Alpha Valuation Engine, the Regime Cross-Sectional model sees the stock as overvalued with a fair value of $0.26 (-96.6%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, 8 of 10 models identify upside from $7.76 to a median fair value of $10.74, indicating the market hasn't fully priced in CorMedix Inc.'s earnings power. | According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +255.4% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology. |
| According to the CirclFi Deep Alpha Valuation Engine, the PWERM model targets a fair value of $20.08 (+158.8%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | Industry headwind: dilutive capital raises represents a meaningful risk for CorMedix Inc. and its Biotechnology peers. |
| Industry tailwind: platform technology validation could provide meaningful support for CorMedix Inc.'s revenue and margin trajectory in the Biotechnology space. |
How Does CRMD Compare to Its Biotechnology Peers?
Valuation data pages: ONC · CGEN · VRTX · VCEL · HALO · PTCT · BOLT · GHRS · ONCO · EXEL · INCY
Which Other Stocks Score Like CRMD on Quality?
Closest companies to CRMD’s Quality of Company score of 9.0/10, across all industries.
- FICO — Fair Isaac Corporation (QOC 9.0) · analysis
- LOGI — Logitech International S.A. (QOC 9.0) · analysis
- SKY — Champion Homes, Inc. (QOC 9.0) · analysis
- DCBO — Docebo Inc. (QOC 9.0) · analysis
- DT — Dynatrace, Inc. (QOC 9.0) · analysis
- XPEL — XPEL, Inc. (QOC 9.0) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Biotechnology Screens Does CRMD Appear In?
So Is CorMedix Inc. (CRMD) Worth Buying in 2026?
The convergence of 9.0/10 quality, multi-model undervaluation (8/10 bullish, +38.4% median upside), and a median fair value of $10.74 vs. $7.76 current price makes CorMedix Inc. one of the more compelling opportunities in our coverage. As always, our models provide a quantitative starting point — not a substitute for individual due diligence.
These are quantitative model outputs, not investment recommendations. CorMedix Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About CRMD Stock?
Should I buy CRMD stock right now?
Based on CirclFi's multi-model analysis, 8 of 10 models see upside for CRMD at $7.76. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 9.0/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in CorMedix Inc.?
Key risks include: wide model disagreement (7507% spread), signaling high uncertainty; general market and sector-specific risks affecting Biotechnology companies. Always diversify and consult a financial advisor.
How does CRMD compare to its competitors?
Among Biotechnology peers, CRMD holds a Quality Score of 9.0/10. Comparable companies include ONC (QOC 9.0), CGEN (QOC 9.0), VRTX (QOC 9.1). The relative ranking helps investors identify whether CRMD offers better fundamental quality than alternatives in the same sector.
Is CRMD a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. CRMD's Quality Score of 9.0/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy CRMD at?
CirclFi does not provide target buy prices or price alerts. However, our 10 active models produce fair value estimates ranging from $0.26 to $20.08. At $7.76, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for CRMD.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad